Table 1.
Patient characteristics.
| Non-secondary cancer (n=3602) | Secondary cancer (n=329) | P | |
|---|---|---|---|
| Age (year) | <0.001 | ||
| median | 59 | 53 | |
| IQR | 52-65 | 43-63 | |
| Race | 0.008 | ||
| asian | 1486 (41.3%) | 106 (32.1%) | |
| black | 422 (11.7%) | 39 (11.9%) | |
| white | 1614 (44.8%) | 173 (52.6%) | |
| other | 80 (2.22%) | 11 (3.34%) | |
| Sex | 0.164 | ||
| female | 1102 (30.6%) | 88 (26.7%) | |
| male | 2500 (69.4%) | 241 (73.3%) | |
| Grade | 0.174 | ||
| I | 56 (1.5%) | 9 (2.8%) | |
| II | 280 (7.7%) | 35 (10.6%) | |
| III | 1119 (31.1%) | 101 (30.7%) | |
| IV | 1133 (31.5%) | 96 (29.2%) | |
| unknown | 1014 (28.2%) | 88 (26.7%) | |
| Pathology | 0.192 | ||
| WHO I | 1124 (31.2%) | 121 (36.8%) | |
| WHO II | 881 (24.5%) | 70 (21.3%) | |
| WHO III | 709 (19.7%) | 59 (17.9%) | |
| other | 888 (24.6%) | 79 (24.0%) | |
| T stage | 0.096 | ||
| 1 | 1148 (31.9%) | 121 (36.8%) | |
| 2 | 927 (25.7%) | 91 (27.7%) | |
| 3 | 739 (20.5%) | 60 (18.2%) | |
| 4 | 788 (21.9%) | 57 (17.3%) | |
| N stage | 0.042 | ||
| 0 | 867 (24.1%) | 101 (30.7%) | |
| 1 | 1218 (33.8%) | 109 (33.1%) | |
| 2 | 1078 (29.9%) | 87 (26.4%) | |
| 3 | 439 (12.2%) | 32 (9.8%) | |
| AJCC | 0.007 | ||
| I | 296 (8.3%) | 42 (12.8%) | |
| II | 916 (25.4%) | 95 (28.9%) | |
| III | 1230 (34.1%) | 104 (31.6%) | |
| IV | 1160 (32.2%) | 88 (26.7%) | |
| Chemotherapy | 0.897 | ||
| no | 445 (12.4%) | 42 (12.8%) | |
| yes | 3157 (87.6%) | 287 (87.2%) |
IQR: interquartile range. WHO: World Health Organization. AJCC: American Joint Committee on Cancer.